Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial

Schizophrenia Research

Volumn 79, Issue 2-3, 2005, Pages 251-256

  Nachshoni, Tali ^a   Ebert, Tanya ^a   Abramovitch, Yehuda ^a,b   Assael Amir, Miriam ^a   Kotler, Moshe ^a,b   Maayan, Rachel ^b   Weizman, Abraham ^b,c   Strous, Rael D ^a,b  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Dehydroepiandrosterone; DHEA; EPS; Extrapyramidal signs; Parkinsonism; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; PRASTERONE;

ADD ON THERAPY; ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL PATIENT; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 26844485651     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.07.029     Document Type: Article

References (21)

1. E.E. Baulieu, and P. Robel Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids J. Endocrinol. 150 1996 S221 S239 (suppl)
2. N. Belanger, L. Gregoire, P. Bedard, and T. Di Paolo Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys Endocrine 21 2003 97 101
3. L.F. Berkman, T.E. Seeman, M. Albert, D. Blazer, R. Kahn, R. Mohs, C. Finch, E. Schneider, C. Cotman, and G. McClearn High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on successful aging J. Clin. Epidemiol. 46 1993 1129 1140
4. J.L. Erb, J.B. Kadane, G. Tourney, R. Mickelsen, D. Trader, R. Szabo, and V. Davis Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements J. Clin. Endocrinol. Metab. 52 1981 181 186
5. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1984. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-P). Version 2. New York: New York State Psychiatric Institute Biometrics Research.
6. E. Friess, T. Schiffelholz, T. Steckler, and A. Steiger Dehydroepiandrosterone: a neurosteoid Eur. J. Clin. Invest. 30 suppl 3 2000 46 50
7. J. Gerlach, and S. Korgard The St. Hans Rating Scale for the extrapyramidal symptoms: reliability and validity Acta Psychiatr. Scand. 87 1993 244 252
8. Guy, W. 1976. ECDEU Assessment: Manual for Psychopharmacology. Rockville, Md: US Dept of Health, Education, and Welfare; National Institute of Mental Health; 218-222. NIMH publication (ADM) 76-338.
9. D.S. Harris, O.M. Wolkowitz, and V.I. Reus Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients World J. Biol. Psychiatry 2 2001 99 102
10. P.D. Kroboth, F.S. Salek, A.L. Pittenger, T.J. Fabian, and R.F. Frye DHEA and DHEA-S: a review J. Clin. Pharmacol. 39 1999 327 328
11. S. Leucht, K. Wahlbeck, J. Hamann, and W. Kissling New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 10,361 2003 1581 1589
12. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, and K. Elgen The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr. Scand. Suppl. 334 1987 1 100
13. H.E. Murray, and G.E. Gillies Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures J. Neuroendocrinol. 9 1997 287 295
14. R.D. Oades, and R. Schepker Serum gonadal steroid hormones in young schizophrenic patients Psychoneuroendocrinology 19 1994 373 385
15. J.E. Overall, and D.R. Gorham The brief rating psychiatric scale Psychol. Rep. 10 1962 799 812
16. S.M. Paul, and R.H. Purdy Neuroactive steroids FASEB J. 6 1992 2311 2322
17. M. Poyurovsky, and A. Weizman Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem Br. J. Psychiatry 179 2001 4 8
18. R. Ruprecht, F. di Michele, B. Hermann, A. Strohle, M. Lancel, E. Romeo, and F. Holsboer Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology Brain Res. Rev. 37 2001 59 67
19. R.D. Strous, R. Maayan, R. Lapidus, R. Stryjer, M. Lustig, M. Kotler, and A. Weizman Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia Arch. Gen. Psychiatry 60 2003 133 141
20. R.D. Strous, R. Maayan, R. Lapidus, L. Goredetsky, E. Zeldich, M. Kotler, and A. Weizman Increased circulatory dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEA-S) in first-episode schizophrenia: relationship to gender, aggression and symptomatology Schizophr. Res. 71 2004 427 434
21. O.M. Wolkowitz, and V.I. Reus Neuropsychiatric effects of dehydroepiandrosterone (DHEA) M. Kalimi W Regelson Dehydroepiandrosterone (DHEA): Biochemical, Physiological and Clinical Aspects 2000 Walter De Gruyter Berlin 271 298